Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET. The call will cover a corporate update and the results for Q4 and the full year 2020. Interested participants can join by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079. The live webcast is accessible via their Investor Relations website.

Viridian focuses on developing treatments for serious diseases, notably VRDN-001, an anti-IGF-1R monoclonal antibody for thyroid eye disease.

BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.

Conference Call & Webcast Details
Date:	Thursday, March 25, 2021
Time:	4:30 pm Eastern Time
Domestic:	877-407-0789
International:	201-689-8562
Conference ID:	13717079
Webcast:	https://investors.viridiantherapeutics.com/events/default.aspx

A live webcast of the conference call can be accessed in the Investors section of Viridian Therapeutics website at https://investors.viridiantherapeutics.com

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids Viridian is headquartered in Boulder, Colorado, with additional operations in Waltham, Massachusetts. Learn more about Viridian and our programs at www.viridiantherapeutics.com.

Follow us on Twitter @ViridianThera and on LinkedIn.

Contacts:

Investors
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com

FAQ

When is the Viridian Therapeutics conference call scheduled?

The conference call for Viridian Therapeutics is scheduled for March 25, 2021, at 4:30 p.m. ET.

How can I access the Viridian Therapeutics conference call?

You can access the conference call by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079.

Where can I find the webcast for the Viridian Therapeutics call?

The live webcast can be found on Viridian Therapeutics' Investor Relations website at https://investors.viridiantherapeutics.com.

What are the key topics for the Viridian Therapeutics conference call?

The conference call will cover a corporate update and discuss the fourth quarter and full-year results for 2020.

What is VRDN-001 being developed for?

VRDN-001 is being developed as a treatment for thyroid eye disease (TED), a debilitating autoimmune disease.